1.41

2.92% +0.04

After Hours: 1.38 -0.03 -2.13%

Carisma Therapeutics Inc (CARM)

Overview News Price History Discussions Forecast Stock Split

Carisma Therapeutics Inc stock is currently priced at $1.41, with a 24-hour trading volume of 221.65K. It has seen a +2.92% increased in the last 24 hours and a -16.57% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.38 pivot point. If it approaches the $1.42 resistance level, significant changes may occur.

Previous Close:

$1.37

Open:

$1.42

24h Volume:

221.65K

Market Cap:

$58.58M

Revenue:

$14.92M

Net Income/Loss:

$-86.88M

P/E Ratio:

-0.4593

EPS:

-3.0699

Net Cash Flow:

$-82.31M

1W Performance:

-4.73%

1M Performance:

-16.57%

6M Performance:

-43.37%

1Y Performance:

-71.05%

1D Range:

$1.35

$1.42

52W Range:

$1.345

$9.7662

Carisma Therapeutics Inc Stock (CARM) Company Profile

Name

Carisma Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

484 899 0326

Address

3675 Market St., Ste. 200, Philadelphia

Employee

Twitter

Next Earnings Date

2024-06-13

Latest SEC Filings

CARM's Discussions on Twitter

Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-06-23	Initiated	Evercore ISI	Outperform
May-31-23	Upgrade	Jefferies	Hold → Buy
May-24-23	Initiated	H.C. Wainwright	Buy
Apr-14-23	Initiated	Robert W. Baird	Outperform

Carisma Therapeutics Inc Stock (CARM) Latest News

Carisma Therapeutics (NASDAQ:CARM) Rating Reiterated by HC Wainwright - Defense World

Defense World

Carisma Therapeutics (NASDAQ:CARM) Rating Reiterated by HC Wainwright - MarketBeat

MarketBeat

The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts - CARISMA Therapeutics (NASDAQ:CARM) - Benzinga

Benzinga

Carisma Therapeutics begins trial for novel cancer therapy - Investing.com

Investing.com

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting ... - PR Newswire

PR Newswire

Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics - PR Web

PR Web

Carisma Therapeutics Inc Stock (CARM) Financials Data

Carisma Therapeutics Inc (CARM) Revenue 2024

CARM reported a revenue (TTM) of $14.92 million for the quarter ending December 31, 2023, a +51.71% rise year-over-year.

Carisma Therapeutics Inc (CARM) Net Income 2024

CARM net income (TTM) was -$86.88 million for the quarter ending December 31, 2023, a -41.90% decrease year-over-year.

Carisma Therapeutics Inc (CARM) Cash Flow 2024

CARM recorded a free cash flow (TTM) of -$82.31 million for the quarter ending December 31, 2023, a -741.95% decrease year-over-year.

Carisma Therapeutics Inc (CARM) Earnings per Share 2024

CARM earnings per share (TTM) was -$3.43 for the quarter ending December 31, 2023, a -125.51% decline year-over-year.

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.